Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Virus Diagnosis Device Delivers Lab-Quality Results within Three Minutes

By LabMedica International staff writers
Posted on 03 Nov 2023

Researchers have developed a device capable of delivering lab-grade viral diagnostic results in just three minutes, offering a rapid and economical solution for detecting COVID-19 from nasal swabs. More...

This technology, according to its developers, is versatile enough to be modified for identifying various pathogens, such as bacteria, and potentially even cancer.

The prototype LoCKAmp device developed by engineers at the University of Bath (Bath, UK) uses advanced 'lab on a chip' technology. The device operates by quickly releasing and amplifying genetic material from a nasal swab sample and facilitating a chemical reaction that produces a result that can be viewed through a smartphone application. The LoCKAmp device differs from the common lateral flow tests used throughout the pandemic by employing the same genetic detection methods previously reserved for laboratory-grade PCR (polymerase chain reaction) tests, delivering rapid lab-level testing to the public for the first time. A key feature of the LoCKAmp is its rapid result time, clocking in at three minutes, making it the fastest COVID-19 test reported so far.

Built using readily available parts and mass-produced circuit boards, the LoCKAmp prototype device can be manufactured quickly and cost-effectively on a large scale. This presents an efficient new tool for healthcare providers and public health authorities globally in the field of virus detection. The research team suggests that with a commercial partner experienced in design and manufacturing, the LoCKAmp could be redesigned into a compact, portable device, ideal for use in areas with limited access to healthcare. Beyond just evaluating nasal swab samples, the LoCKAmp technology also has the potential for anonymous, community-level virus monitoring by testing samples from sources such as wastewater.

“This is an amazing display of the possibilities of lab-on-a-chip technology, and given the low cost and adaptability of the technology to detect a range of conditions, a potentially highly valuable and unique tool for a range of healthcare settings,” said Dr. Despina Moschou from the University of Bath who led the research.

Related Links:
University of Bath


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.